On Thursday, Shares of National Bank of Greece S.A. (NYSE:NBG), lost -0.76% to $1.31, as Greece has once again failed to reach a deal with its creditors.
Euro zone finance ministers ended their third meeting in a week with no agreement. The country’s three international creditors put forth a final cash reform proposal in its battle with the Greek government, Reuters reports.
For months Greece and its creditors have been meeting in order to work out a deal that would keep the debt-riddled country from defaulting and possibly exiting the euro zone.
Greece must make a 1.54 billion euro payment to the International Monetary Fund at the end of the month, which is next week, or risk bankruptcy.
Another meeting will be held on Saturday as a final effort to avoid a Greek debt default, Reuters noted.
National Bank of Greece S.A., together with its auxiliaries, provides diversified financial services. The company is involved in retail and commercial banking, asset administration, investment banking, brokerage, and insurance activities.
Shares of AbbVie Inc. (NYSE:ABBV), inclined 0.87% to $69.82, during its last trading session.
AbbVie, declared TURQUOISE-III study results demonstrating 100 percent (n=60/60) sustained virologic response at 12 weeks post-treatment (SVR12) in genotype 1b (GT1b) chronic hepatitis C virus (HCV) infected adult patients with compensated liver cirrhosis.1 Patients received 12 weeks of VIEKIRAX® (ombitasvir/paritaprevir/ritonavir tablets) + EXVIERA® (dasabuvir tablets) without ribavirin (RBV). These new results from AbbVie’s Phase 3b study will be presented at the 15th Annual International Symposium on Viral Hepatitis and Liver Diseases in Berlin, Germany.
About 160 million people worldwide are infected with HCV. Genotype 1 is the most common type of HCV genotype, accounting for 60 percent of cases worldwide and in Europe, the most prevalent genotype is 1b (47 percent). Over time, chronic HCV may lead to liver complications, counting compensated cirrhosis, in about 10-20 percent of people infected.
“Genotype 1b represents a large portion of HCV patients globally, as it is the most prevalent sub-genotype, and there is a need to continue to explore additional treatment regimens,” said Jordan J. Feld, M.D., MPH, research director and clinician scientist, Toronto Center for Liver Disease, Toronto, Canada. “The results of TURQUOISE-III are promising, demonstrating that genotype 1b HCV patients with compensated liver cirrhosis have the potential to achieve high response rates with an interferon and ribavirin-free treatment in 12 weeks.”
AbbVie Inc. discovers, develops, manufactures, and sells pharmaceutical products worldwide. The company’s products comprise HUMIRA, a biologic therapy administered as a subcutaneous injection to treat autoimmune diseases; VIEKIRA PAK, an all-oral, short-course, interferon-free therapy, with or without ribavirin, for adult patients with genotype 1 chronic hepatitis, counting those with compensated cirrhosis; Kaletra, an anti-HIV-1 medicine used with other anti-HIV-1 medications as a treatment that maintains viral suppression in people with HIV-1.
Finally, Sabra Health Care REIT, Inc. (NASDAQ:SBRA), ended its last trade with -3.46% loss, and closed at $25.40.
Sabra Health Care REIT, declared the pricing of a formerly declared underwritten public offering of 5,900,000 shares of Sabra’s common stock, which is predictable to result in gross proceeds to Sabra of about $149 million. Sabra anticipates to issue and deliver the shares of its common stock on or about June 30, 2015, subject to customary closing conditions.
Sabra intends to use the net proceeds from the offering to repay borrowings outstanding on Sabra’s revolving credit facility. Any remaining proceeds to Sabra will be used to fund possible future acquisitions or for general corporate purposes.
Wells Fargo Securities and J.P. Morgan are acting as joint bookrunning managers for this offering.
Sabra Health Care REIT, Inc. operates as a real estate investment trust in the United States. The company, through its auxiliaries, owns and invests in real estate properties for the healthcare industry. Its property portfolio comprises of 86 properties comprising 67 skilled nursing facilities; 10 combined skilled nursing, assisted living, and independent living facilities; 5 assisted living facilities; 2 mental health facilities; 1 independent living facility; and 1 ongoing care retirement community.
DISCLAIMER:
This article is published by www.wsnewspublishers.com. The Content included in this article is just for informational purposes only. All information used in this article is believed to be from reliable sources, but we make no representations or warranties of any kind, express or implied, about the completeness, accuracy, or reliability with respect to this article.
All visitors are advised to conduct their own independent research into individual stocks before making a purchase decision.
Information contained in this article contains forward-looking information within the meaning of Section 27A of the Securities Act of 1933 and Section 21E of the Securities Exchange Act of 1934, counting statements regarding the predictable continual growth of the market for the corporation’s products, the corporation’s ability to fund its capital requirement in the near term and in the long term; pricing pressures; etc.
Any statements that express or involve discussions with respect to predictions, expectations, beliefs, plans, projections, objectives, aims, assumptions, or future events or performance may be forward looking statements. Forward-looking statements are based on expectations, estimates, and projections at the time the statements are made that involve a number of risks and uncertainties which could cause actual results or events to differ materially from those presently anticipated. Forward looking statements may be identified through the use of such words as expects, will, anticipates, estimates, believes, or by statements indicating certain actions may, could, should/might occur.
